Table 3 The effects on steatosis of exposure to specific antiretroviral medication in 184 HIV-HCV coinfected patients

Nucleoside reverse transcriptase inhibitors

184

NE

1.05 (0.961.16)

0.30

zidovudine

144

1.11 (0.54-2.30)

0.77

1.03 (0.91-1.16)

0.65

lamivudine

161

1.10 (0.44-2.77)

0.82

1.01 (0.88-1.17)

0.84

stavudine

114

0.96 (0.51-1.78)

0.88

1.05 (0.90-1.24)

0.54

didanosine

105

1.20 (0.66-2.18)

0.57

1.04 (0.85-1.27)

0.70

zalcitabine

22

1.68 (0.60-4.72)

0.33

1.50 (0.68-3.34)

0.31

tenofovir

24

0.87 (0.33-2.27)

0.78

1.19 (0.69-2.07)

0.53

abacavir

24

0.55 (0.22-1.39)

0.20

0.98 (0.69-1.41)

0.94

Protease inhibitors

126

1.15 (0.59-2.24)

0.67

1.06 (0.90-1.25)

0.50

ritonavir

55

0.90 (0.46-1.75)

0.75

0.96 (0.71-1.28)

0.76

indinavir

68

0.94 (0.51-1.74)

0.84

1.14 (0.87-1.47)

0.34

nelfinavir

47

0.96 (0.48-1.89)

0.91

1.12 (0.79-1.59)

0.54

saquinavir

31

0.91 (0.41-2.00)

0.81

0.72 (0.45-1.14)

0.16

lopinavir-ritonavir

17

0.55 (0.19-1.63)

0.28

0.86 (0.54-1.37)

0.52

atazanavir

8

0.76 (0.17-3.43)

0.72

0.99 (0.35-2.81)

0.98

Non-nucleoside reverse transcriptase inhibitors

79

0.93 (0.50-1.74)

0.81

1.17 (0.88-1.55)

0.27

efavirenz

51

1.34 (0.67-2.69)

0.40

1.19 (0.88-1.63)

0.26

nevirapine

44

0.67 (0.33-1.35)

0.26

1.24 (0.77-2.00)

0.36